Drug Trial Radar · NCT04495153
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Actual
Start
Oct 13, 2020
Primary completion
Dec 31, 2024
Study completion Dec 2027
Sponsor
- Lead sponsor
- Candel Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- NYU Langone Health
- First posted
- Jul 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.
Conditions
- Non Small Cell Lung Cancer
Interventions
Aglatimagene besadenovecBiological
Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) via intratumoral injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.
ValacyclovirDrug
Oral, for 14 days following each aglatimagene besadenovec injection
Standard of Care anti-PD-1/PD-L1 (ICI)Biological
Standard of care ICI such as Pembrolizumab, Nivolumab, Durvalumab every 2, 3, 4, or 6 weeks per SOC regimen
ChemotherapyDrug
Standard of care, ongoing maintenance chemotherapy (if applicable) such as Cisplatin/Carboplatin + Pemetrexed or Paclitaxel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rateTime frame: 12 months
- Safety graded by CTCAE version 5.0Time frame: 12 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
UConn Health
Farmington, Connecticut
Yale University, Yale Cancer Center
New Haven, Connecticut
University of Chicago
Chicago, Illinois
University of Maryland, Baltimore
Baltimore, Maryland
Mayo Clinic
Rochester, Minnesota
NYU Langone Health
New York, New York
The Ohio State University Wexner Medical Center
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Utah
Salt Lake City, Utah
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia
Virginia Commonwealth University
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.